Thrombotic Microangiopathy Following Y<sup>90</sup>-Dotatate Treatment
November 08, 2019 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
Thrombotic Microangiopathy Following Y90-Dotatate Treatment
Electrolytes and Cancer Trainee Case Reports
November 08, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Trainee Case Report
- 1500 Onco-Nephrology
- Griffiths, Kathryn Jane, Epsom and St Helier University Hospital NHS Trust, London, United Kingdom
- Swift, Pauline A., Epsom and St Helier University Hospital NHS Trust, London, United Kingdom
- Doshi, Rukma, Epsom and St Helier University Hospital NHS Trust, London, United Kingdom
- Sood, Bhrigu Raj, Epsom and St Helier University Hospital NHS Trust, London, United Kingdom
Kathryn Jane Griffiths,
Pauline A. Swift,
Bhrigu Raj Sood,
Gastro-entero-pancreatic neuroendocrine tumours are rare; the expression of somatostatin receptors enables treatment with radiolabelled somatostatin analogues such as Yttrium labelled octreotide (Y90-dotatate). Patients are routinely consented for non-specific renal toxicity prior to treatment.
We present the case of a 49 year old woman with a well differentiated neuroendocrine tumour. She was treated with lanreotide (long acting somatostatin analogue) but follow up scans demonstrated progressive disease and she was then treated with three cycles of Y90-Dotatate therapy (4.0 GBq).
Four months later she presented with shortness of breath with a haemoglobin of 69 g/L, platelet count of 132 x 109/L and creatinine of 145 umol/L. She had previously normal renal function. Over the following days the platelet count fell further to 55 x 109/L at the lowest and she was hypertensive. A blood film demonstrated fragments. Three stool cultures were negative for shigella toxin and e.coli. An ADAMST13 demonstrated >10% activity. She was commenced on plasma exchange, receiving five 1.5L cycles with fresh frozen plasma. The case was discussed with the National Renal Complement Therapeutics Centre, Newcastle, UK. It was thought that this was not in keeping with a complement driven process amenable to Eculizumab treatment. The platelet count gradually increased to normal range with the haemoglobin remaining stable around 80g/L during plasma exchange. A renal biopsy was performed which demonstrated morphological features compatible with a TMA. Since stopping plasma exchange, the patient has been followed up in the renal clinic, with focus on good blood pressure control but renal function appears to be declining slowly.
TMA has been described in association with Y90-Dotate therapy and this case demonstrates this rare complication which carries a poor renal prognosis.
Renal biopsy: glomerulus showing thrombi in capillary loops and basement membrane thickening; mesangiolysis; aneurysmal dilatation of capillary loops; background acute tubular necrosis.